Roche Remains Positive After Tecentriq Triple-Negative Breast Cancer Data
Executive Summary
Clinicians and the company have heralded the IMpassion130 data presented at ESMO which showed that Roche's Tecentriq is the first immunotherapy to improve outcomes in TNBC but a slight blot on the landscape is that pretty much all of the survival benefit was seen in breast cancer patients with PD-L1 positive tumors.
You may also be interested in...
Approval Positions Roxadustat As Japan HIF-PHI Pioneer
The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.
Roche's Tecentriq Steals Lead In Triple-Negative Breast Cancer
The PD-L1 inhibitor is the first checkpoint immunotherapy to gain approval in the tough-to-treat disease setting.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.